{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T06:10:40Z","timestamp":1774937440463,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T00:00:00Z","timestamp":1538006400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009664","name":"Sociedad Espa\u00f1ola de Cardiolog\u00eda","doi-asserted-by":"publisher","award":["SEC-CNIC CARDIOJOVEN Program"],"award-info":[{"award-number":["SEC-CNIC CARDIOJOVEN Program"]}],"id":[{"id":"10.13039\/100009664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00392-018-1378-0","type":"journal-article","created":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T10:09:01Z","timestamp":1538042941000},"page":"477-486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials"],"prefix":"10.1007","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6783-8463","authenticated-orcid":false,"given":"Xavier","family":"Rossello","sequence":"first","affiliation":[]},{"given":"Cono","family":"Ariti","sequence":"additional","affiliation":[]},{"given":"Stuart J.","family":"Pocock","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Nicolas","family":"Girerd","sequence":"additional","affiliation":[]},{"given":"John J. V.","family":"McMurray","sequence":"additional","affiliation":[]},{"given":"Dirk J.","family":"Van Veldhuisen","sequence":"additional","affiliation":[]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2018,9,27]]},"reference":[{"key":"1378_CR1","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","volume":"353","author":"MERIT-HF-Investigators","year":"1999","unstructured":"MERIT-HF-Investigators (1999) Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 353:2001\u20132007","journal-title":"Lancet"},{"key":"1378_CR2","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/S0735-1097(98)00609-3","volume":"33","author":"MJ Domanski","year":"1999","unstructured":"Domanski MJ, Exner DV, Borkowf CB et al (1999) Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 33:598\u2013604","journal-title":"J Am Coll Cardiol"},{"key":"1378_CR3","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1093\/eurheartj\/ehv186","volume":"36","author":"AS Desai","year":"2015","unstructured":"Desai AS, McMurray JJV, Packer M et al (2015) Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J 36:1990\u20131997. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehv186","journal-title":"Eur Heart J"},{"key":"1378_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609758","volume":"377","author":"L Shen","year":"2017","unstructured":"Shen L, Jhund PS, Petrie MC et al (2017) Declining risk of sudden death in heart failure. N Engl J Med 377:41\u201351. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1609758","journal-title":"N Engl J Med"},{"key":"1378_CR5","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","volume":"375","author":"L K\u00f8ber","year":"2016","unstructured":"K\u00f8ber L, Thune JJ, Nielsen JC et al (2016) Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 375:1221\u20131230. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1608029","journal-title":"N Engl J Med"},{"key":"1378_CR6","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129\u20132200. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehw128","journal-title":"Eur Heart J"},{"key":"1378_CR7","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","volume":"62","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B et al (2013) 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62:e147\u2013e239. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2013.05.019","journal-title":"J Am Coll Cardiol"},{"key":"1378_CR8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709\u2013717. \n                    https:\/\/doi.org\/10.1056\/NEJM199909023411001","journal-title":"N Engl J Med"},{"key":"1378_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJV, Krum H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11\u201321. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1009492","journal-title":"N Engl J Med"},{"key":"1378_CR10","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F et al (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309\u20131321. \n                    https:\/\/doi.org\/10.1056\/NEJMoa030207","journal-title":"N Engl J Med"},{"key":"1378_CR11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ahj.2017.09.010","volume":"195","author":"M Bossard","year":"2018","unstructured":"Bossard M, Binbraik Y, Beygui F et al (2018) Mineralocorticoid receptor antagonists in patients with acute myocardial infarction\u2014a systematic review and meta-analysis of randomized trials. Am Heart J 195:60\u201369. \n                    https:\/\/doi.org\/10.1016\/j.ahj.2017.09.010","journal-title":"Am Heart J"},{"key":"1378_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2165\/00129784-200707010-00007","volume":"7","author":"M Guglin","year":"2007","unstructured":"Guglin M, Awad KE, Polavaram L, Vankayala H (2007) Aldosterone antagonists: the most underutilized class of heart failure medications. Am J Cardiovasc Drugs 7:75\u201379","journal-title":"Am J Cardiovasc Drugs"},{"key":"1378_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s00392-017-1161-7","volume":"107","author":"V Bistola","year":"2018","unstructured":"Bistola V, Simitsis P, Farmakis D et al (2018) Association of mineralocorticoid receptor antagonist use and in-hospital outcomes in patients with acute heart failure. Clin Res Cardiol 107:76\u201386. \n                    https:\/\/doi.org\/10.1007\/s00392-017-1161-7","journal-title":"Clin Res Cardiol"},{"key":"1378_CR14","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1161\/01.CIR.0000138973.55605.38","volume":"110","author":"E Perrier","year":"2004","unstructured":"Perrier E, Kerfant B-G, Lalevee N et al (2004) Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction. Circulation 110:776\u2013783. \n                    https:\/\/doi.org\/10.1161\/01.CIR.0000138973.55605.38","journal-title":"Circulation"},{"key":"1378_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/BF00877755","volume":"9","author":"B Pitt","year":"1995","unstructured":"Pitt B (1995) \u201cEscape\u201d of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc drugs Ther 9:145\u2013149","journal-title":"Cardiovasc drugs Ther"},{"key":"1378_CR16","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1161\/CIRCULATIONAHA.104.503706","volume":"111","author":"A Ouvrard-Pascaud","year":"2005","unstructured":"Ouvrard-Pascaud A, Sainte-Marie Y, B\u00e9nitah J-P et al (2005) Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 111:3025\u20133033. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.104.503706","journal-title":"Circulation"},{"key":"1378_CR17","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1161\/CIRCHEARTFAILURE.112.000003","volume":"6","author":"SR Bapoje","year":"2013","unstructured":"Bapoje SR, Bahia A, Hokanson JE et al (2013) Effects of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction: a meta-analysis of randomized controlled trials. Circ Heart Fail 6:166\u2013173. \n                    https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.112.000003","journal-title":"Circ Heart Fail"},{"key":"1378_CR18","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1093\/eurheartj\/ehu424","volume":"41","author":"BR Costa da","year":"2014","unstructured":"da Costa BR, J\u00fcni P (2014) Systematic reviews and meta-analyses of randomized trials: principles and pitfalls. Eur Heart J 41:3336\u20133345. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehu424","journal-title":"Eur Heart J"},{"key":"1378_CR19","doi-asserted-by":"publisher","first-page":"c221","DOI":"10.1136\/bmj.c221","volume":"340","author":"RD Riley","year":"2010","unstructured":"Riley RD, Lambert PC, Abo-Zaid G (2010) Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 340:c221","journal-title":"BMJ"},{"key":"1378_CR20","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/ejhf.688","volume":"19","author":"P Rossignol","year":"2017","unstructured":"Rossignol P, Girerd N, Bakris G et al (2017) Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. Eur J Heart Fail 19:792\u2013799. \n                    https:\/\/doi.org\/10.1002\/ejhf.688","journal-title":"Eur J Heart Fail"},{"key":"1378_CR21","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1056\/NEJMoa043938","volume":"352","author":"SD Solomon","year":"2005","unstructured":"Solomon SD, Zelenkofske S, McMurray JJV et al (2005) Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 352:2581\u20132588. \n                    https:\/\/doi.org\/10.1056\/NEJMoa043938","journal-title":"N Engl J Med"},{"key":"1378_CR22","doi-asserted-by":"publisher","first-page":"e0145958","DOI":"10.1371\/journal.pone.0145958","volume":"11","author":"H-H Le","year":"2016","unstructured":"Le H-H, El-Khatib C, Mombled M et al (2016) Impact of aldosterone antagonists on sudden cardiac death prevention in heart failure and post-myocardial infarction patients: a systematic review and meta-analysis of randomized controlled trials. PLoS One 11:e0145958. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0145958","journal-title":"PLoS One"},{"key":"1378_CR23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1056\/NEJMoa043399","volume":"352","author":"GH Bardy","year":"2005","unstructured":"Bardy GH, Lee KL, Mark DB et al (2005) Amiodarone or an implantable cardioverter\u2013defibrillator for congestive heart failure. N Engl J Med 352:225\u2013237. \n                    https:\/\/doi.org\/10.1056\/NEJMoa043399","journal-title":"N Engl J Med"},{"key":"1378_CR24","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1056\/NEJMoa1514859","volume":"374","author":"JJV McMurray","year":"2016","unstructured":"McMurray JJV, Krum H, Abraham WT et al (2016) Aliskiren, enalapril, or aliskiren and enalapril in heart failure. N Engl J Med 374:1521\u20131532. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1514859","journal-title":"N Engl J Med"},{"key":"1378_CR25","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1001\/archinternmed.2011.468a","volume":"172","author":"AL Miller","year":"2012","unstructured":"Miller AL, Wang Y, Curtis J et al (2012) Optimal medical therapy use among patients receiving implantable cardioverter\/defibrillators: insights from the National Cardiovascular Data Registry. Arch Intern Med 172:64\u201367. \n                    https:\/\/doi.org\/10.1001\/archinternmed.2011.466","journal-title":"Arch Intern Med"},{"key":"1378_CR26","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.ahj.2011.01.027","volume":"161","author":"GC Fonarow","year":"2011","unstructured":"Fonarow GC, Yancy CW, Hernandez AF et al (2011) Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. Am Heart J 161:1024\u20131030. \n                    https:\/\/doi.org\/10.1016\/j.ahj.2011.01.027","journal-title":"Am Heart J"},{"key":"1378_CR27","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMsa051989","volume":"353","author":"GD Sanders","year":"2005","unstructured":"Sanders GD, Hlatky MA, Owens DK (2005) Cost-effectiveness of implantable cardioverter\u2013defibrillators. N Engl J Med 353:1471\u20131480. \n                    https:\/\/doi.org\/10.1056\/NEJMsa051989","journal-title":"N Engl J Med"},{"key":"1378_CR28","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa013474","volume":"346","author":"AJ Moss","year":"2002","unstructured":"Moss AJ, Zareba W, Hall WJ et al (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346:877\u2013883. \n                    https:\/\/doi.org\/10.1056\/NEJMoa013474","journal-title":"N Engl J Med"},{"key":"1378_CR29","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1054\/jcaf.2000.9503","volume":"6","author":"EJ Stanek","year":"2000","unstructured":"Stanek EJ, Oates MB, McGhan WF et al (2000) Preferences for treatment outcomes in patients with heart failure: symptoms versus survival. J Card Fail 6:225\u2013232. \n                    https:\/\/doi.org\/10.1054\/jcaf.2000.9503","journal-title":"J Card Fail"},{"key":"1378_CR30","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.hrthm.2009.02.005","volume":"6","author":"BS Stambler","year":"2009","unstructured":"Stambler BS, Laurita KR, Shroff SC et al (2009) Aldosterone blockade attenuates development of an electrophysiological substrate associated with ventricular tachyarrhythmias in heart failure. Heart Rhythm 6:776\u2013783. \n                    https:\/\/doi.org\/10.1016\/j.hrthm.2009.02.005","journal-title":"Heart Rhythm"},{"key":"1378_CR31","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00392-015-0945-x","volume":"105","author":"JP Ferreira","year":"2016","unstructured":"Ferreira JP, Girerd N, Medeiros PB et al (2016) Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect. Clin Res Cardiol 105:489\u2013507. \n                    https:\/\/doi.org\/10.1007\/s00392-015-0945-x","journal-title":"Clin Res Cardiol"},{"key":"1378_CR32","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1161\/01.CIR.100.12.1311","volume":"100","author":"HA Cooper","year":"1999","unstructured":"Cooper HA, Dries DL, Davis CE et al (1999) Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 100:1311\u20131315","journal-title":"Circulation"},{"key":"1378_CR33","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1093\/eurheartj\/ehx460","volume":"38","author":"M Aldahl","year":"2017","unstructured":"Aldahl M, Jensen A-SC, Davidsen L et al (2017) Associations of serum potassium levels with mortality in chronic heart failure patients. Eur Heart J 38:2890\u20132896. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehx460","journal-title":"Eur Heart J"},{"key":"1378_CR34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ahj.2017.03.011","volume":"188","author":"D Vukadinovi\u0107","year":"2017","unstructured":"Vukadinovi\u0107 D, Lavall D, Vukadinovi\u0107 AN et al (2017) True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: a meta-analysis. Am Heart J 188:99\u2013108. \n                    https:\/\/doi.org\/10.1016\/j.ahj.2017.03.011","journal-title":"Am Heart J"},{"key":"1378_CR35","doi-asserted-by":"publisher","first-page":"c1768","DOI":"10.1136\/bmj.c1768","volume":"340","author":"L Wei","year":"2010","unstructured":"Wei L, Struthers AD, Fahey T et al (2010) Spironolactone use and renal toxicity: population based longitudinal analysis. BMJ 340:c1768\u2013c1768. \n                    https:\/\/doi.org\/10.1136\/bmj.c1768","journal-title":"BMJ"},{"key":"1378_CR36","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1410853","volume":"372","author":"MR Weir","year":"2015","unstructured":"Weir MR, Bakris GL, Bushinsky DA et al (2015) Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 372:211\u2013221. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1410853","journal-title":"N Engl J Med"},{"key":"1378_CR37","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/ejhf.31","volume":"16","author":"J Iqbal","year":"2014","unstructured":"Iqbal J, Parviz Y, Pitt B et al (2014) Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure. Eur J Heart Fail 16:143\u2013150. \n                    https:\/\/doi.org\/10.1111\/ejhf.31","journal-title":"Eur J Heart Fail"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-018-1378-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00392-018-1378-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-018-1378-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T20:01:39Z","timestamp":1569528099000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00392-018-1378-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,27]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["1378"],"URL":"https:\/\/doi.org\/10.1007\/s00392-018-1378-0","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,27]]},"assertion":[{"value":"31 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"XR, CA, SJP, and DJVV have nothing to declare. JMcM reports conflicts of interest from Roche Pharmaceuticals, during the conduct of the study; other from Novartis, Cardiorentis, Amgen Oxford University\/Bayer, GlaxoSmithKline, Theracos, Abbvie, DalCor, Pfizer, Merck, AstraZeneca Bristol Myers Squibb (BMS), Kidney Research UK (KRUK)\/Kings College Hospital, London\/Vifor-Fresenius Pharma, outside the submitted work. BP reports personal fees from Bayer, personal fees from KDP pharmaceuticals, and personal fees from Astrazeneca, outside the submitted work; In addition, BP has a patent site-specific delivery of eplerenone to the myocardium pending to university of Michigan. Faiez Zannad received honoraria and\/or travel fees for participation in clinical trial committees and meetings\/presentations from Amgen, AstraZeneca, Bayer, Boehringer, Boston Scientific, GE Healthcare, CVRx, Relypsa\/Vifor-Fresenius, J&J, Pfizer, Novartis, Quantum Genomics, Resmed, Takeda, and received honoraria and\/or travel fees for participation in advisory boards from BMS, KBP BioSciences, Livanova, NovoNordisk, Roche, ZS Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}